Dr. Reddy's Laboratories Ltd.
on Wednesday announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the U.S. Food and Drug Administration (USFDA).
"We are pleased to be among the first generics to launch this product," explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's Laboratories. "This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment."
The EMEND® for Injection brand had an US sales of approximately $279mn MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.
Dr Reddys Laboratories Ltd is currently trading at Rs2,744.20 down by Rs4.2 or 0.15% from its previous closing of Rs2,748.40 on the BSE.
The scrip opened at Rs2,747.65 and has touched a high and low of Rs2,777.90 and Rs2,742 respectively. So far 5,23,320 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs45,663.50cr.